UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 3, 2021

MYRIAD GENETICS, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) 0-26642 (Commission File Number) 87-0494517 (IRS Employer Identification No.)

320 Wakara Way Salt Lake City, Utah 84108 (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (801) 584-3600

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:					
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)				
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)				
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))				
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))				
Securit	ies registered pursuant to Section 12(b) of the Act:				
	Title of each class	Trading Symbol(s)	Name of each exchange on which registered		
	Common Stock, \$0.01 par value	MYGN	Nasdaq Global Select Market		
	Common Stock, \$0.01 par value e by check mark whether the registrant is an emergir or Rule 12b-2 of the Securities Exchange Act of 19	MYGN ng growth company as defined in Rule 4	•		
hapter	e by check mark whether the registrant is an emergin	MYGN ng growth company as defined in Rule 4	•		
chapter Emergi f an en	e by check mark whether the registrant is an emergin) or Rule 12b-2 of the Securities Exchange Act of 19 ng growth company	mygn ng growth company as defined in Rule 4 934 (§240.12b-2 of this chapter). the registrant has elected not to use the	405 of the Securities Act of 1933 (§230.405 of this extended transition period for complying with any new		
chapter Emergi f an en	e by check mark whether the registrant is an emergin) or Rule 12b-2 of the Securities Exchange Act of 19 ng growth company nerging growth company, indicate by check mark if	mygn ng growth company as defined in Rule 4 934 (§240.12b-2 of this chapter). the registrant has elected not to use the	405 of the Securities Act of 1933 (§230.405 of this extended transition period for complying with any new		

ITEM 5.07 Submissions of Matters to a Vote of Security Holders.

On June 3, 2021, Myriad Genetics, Inc. (the "Company") held its 2021 Annual Meeting of Stockholders (the "Annual Meeting"). Of the 77,000,430 shares of Company common stock outstanding as of the record date of April 8, 2021, a quorum of 69,290,013 shares, or approximately 89.98% of the outstanding shares of Company common stock, was present in person (via webcast) or represented by proxy.

The following is a brief description of each matter submitted to a vote at the Annual Meeting, as well as the number of votes cast for and against and the number of abstentions and broker non-votes with respect to each matter.

Proposal No. 1: Election of Directors

To elect S. Louise Phanstiel, Daniel M. Skovronsky, M.D., Ph.D., and Daniel K. Spiegelman to serve until the 2024 Annual Meeting of Stockholders, and until his or her successor is duly elected and qualified or until his or her earlier death, resignation, retirement or removal.

	Votes For	Votes Against	Votes Abstained	Broker Non-Votes
S. Louise Phanstiel	59,900,449	4,190,306	20,509	5,178,749
Daniel M. Skovronsky, M.D., Ph.D.	63,765,877	330,705	14,682	5,178,749
Daniel K. Spiegelman	63,380,731	705,361	25,172	5,178,749

Proposal No. 2: Ratification of the Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2021

Votes	Votes	Votes	
For	Against	Abstained	
67,469,474	1,810,616	9,923	

Proposal No. 3: Approval, on an Advisory Basis, of the Compensation of Our Named Executive Officers, as Disclosed in the Proxy Statement

Votes	Votes	Votes	Broker
For	Against	Abstained	Non-Votes
62,380,220	1,697,829	33,215	

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MYRIAD GENETICS, INC.

Date: June 3, 2021 By: /s/ R. Bryan Riggsbee

R. Bryan Riggsbee Chief Financial Officer